TCM
IOVA icon

Tekla Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Tekla Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-468,538
Closed -$12.2M – 186
2021
Q2 		$12.2M Sell
468,538
-52,057
-10% -$1.35M 0.4% 65
2021
Q1 		$16.5M Buy
520,595
+249,522
+92% +$10.3M 0.57% 48
2020
Q4 		$12.6M Hold
271,073
– – 0.44% 67
2020
Q3 		$8.92M Hold
271,073
– – 0.33% 71
2020
Q2 		$7.44M Buy
271,073
+50,000
+23% +$1.64M 0.28% 78
2020
Q1 		$6.62M Sell
221,073
-22,410
-9% -$594K 0.3% 68
2019
Q4 		$6.74M Buy
243,483
+68,471
+39% +$1.56M 0.25% 86
2019
Q3 		$3.19M Sell
175,012
-24,061
-12% -$532K 0.14% 112
2019
Q2 		$4.88M Sell
199,073
-17,835
-8% -$269K 0.2% 92
2019
Q1 		$2.06M Hold
216,908
– – 0.08% 129
2018
Q4 		$1.92M Hold
216,908
– – 0.08% 134
2018
Q3 		$2.44M Buy
216,908
+183,513
+550% +$2.6M 0.09% 138
2018
Q2 		$427K Buy
+33,395
New +$488K 0.02% 171

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Tekla Capital Management's IOVA Position: Q3 2021 in Review

Tekla Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2021, closing a stake of 468,538 shares — an estimated $12.2M sold.

Tekla Capital Management first reported a position in IOVA in Q2 2018 and held it in 13 quarters. The position peaked at $16.5M in Q1 2021. 243 funds tracked by Wall St. Rank hold IOVA as of Q3 2021.

  • Tekla Capital Management reported no remaining Iovance Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Tekla Capital Management sold 468,538 Iovance Biotherapeutics shares in Q3 2021, an estimated $12.2M.
  • Tekla Capital Management first reported a position in Iovance Biotherapeutics in Q2 2018 and held it in 13 quarters.
  • Tekla Capital Management's Iovance Biotherapeutics position peaked at $16.5M in Q1 2021.
  • 243 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2021.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.